Please provide an overview of pembrolizumab-induced diabetes type 1.

Comment by InpharmD Researcher

The exact incidence of pembrolizumab-induced type 1 diabetes mellitus varies; expert consensus estimates the overall incidence of immune checkpoint inhibitor–associated diabetes mellitus (CIADM) at approximately 0.4 to 1.0%. However, according to one small retrospective review, ICI-induced diabetes occurred more frequently with pembrolizumab (2.2%) when compared with nivolumab (1%) and ipilimumab (0%) Observational data often suggest an association with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, including pembrolizumab, with potentially greater risk with combination immune checkpoint inhibitor therapy (e.g., PD-1/PD-L1 and cytotoxic T-lymphocyte–associated protein 4 [CTLA-4] inhibitors). Reported time of onset varies widely and ranges from months to several years after treatment initiation, with diabetic ketoacidosis (DKA) being a common initial presentation. Pharmacologic prevention is not established; therefore, guidelines emphasize early recognition through close glucose monitoring, with one recommending monitoring within the first 2 weeks of treatment, after corticosteroid initiation or dose increases, and every 4 weeks thereafter. Established CIADM typically requires lifelong insulin therapy due to profound, persistent beta-cell loss; urgent endocrinology consultation and temporary withholding of immunotherapy may be warranted during DKA or severe metabolic instability.
Background

Guidelines published by the American Society of Clinical Oncology address management of immune-related adverse events in patients treated with immune checkpoint inhibitors, including autoimmune diabetes resulting from pembrolizumab toxicity. The guidelines emphasize early recognition of abrupt insulin deficiency and diabetic ketoacidosis (DKA), but do not specifically note any evidence of preventive medications. The discussed management recommendations largely reflect expert consensus. Patients developing new cases of polyuria, polydipsia, weight loss, or lethargy should undergo prompt assessment of glucose, electrolytes, anion gap, ketones, and acid-base status, with C-peptide, insulin, and pancreatic autoantibodies obtained to support diagnosis without delaying treatment. When autoimmune diabetes is suspected, insulin initiation and urgent endocrinology consultation are recommended, with hospitalization appropriate if timely outpatient management is unavailable, even without established DKA. For grade 2 toxicity, including autoimmune diabetes without ketoacidosis, immunotherapy may be withheld until glucose is controlled, whereas grade 3-4 toxicity requires treatment interruption until improvement to grade 1 or less and inpatient management when DKA is present. Because long-acting insulin alone cannot adequately replace lost pancreatic function, the suggested starting total daily insulin requirement is 0.3-0.4 units/kg/day. Immunosuppression is not indicated, while permanent immunotherapy discontinuation is generally unnecessary when endocrine dysfunction is controlled with replacement therapy. [1]

A comprehensive 2025 consensus paper discusses several guidelines, including the American Society of Clinical Oncology, Society for Immunotherapy of Cancer, and European Society for Medical Oncology. While not specific to pembrolizumab only, checkpoint inhibitor-­associated autoimmune diabetes mellitus (CIADM) occurs in approximately 0.4%-1.9% of ICI-treated patients and is associated almost exclusively with anti-PD-1/anti-PD-L1 therapy, with greater risk when these agents are combined with anti-CTLA-4 therapy. Median onset is approximately 12 weeks after treatment initiation, although cases occurring years after initiation demonstrate that risk persists beyond the early treatment period. Presentation is frequently abrupt, with diabetic ketoacidosis (DKA) present in 45%-67% of cases at diagnosis. These estimates should be distinguished from the substantially higher frequency of hyperglycemia from all causes during ICI therapy, which includes corticosteroid effects and pre-existing type 2 diabetes. [2]

Diagnosis of CIADM requires new-onset hyperglycemia, defined as glucose ≥11.1 mmol/L (approximately 200 mg/dL) and/or HbA1c ≥6.5%, together with a low C-peptide concentration of <0.4 nmol/L within one month of presentation. Distinguishing autoimmune insulin deficiency from steroid-induced hyperglycemia and pancreatitis-associated diabetes is essential because their treatment requirements differ.The consensus does not identify a pharmacologic intervention proven to prevent CIADM. For patients starting an ICI without additional hyperglycemia risk factors, glucose testing is recommended with each treatment cycle, together with HbA1c every three months. Patients commencing corticosteroids or developing elevated lipase warrant closer monitoring, preferably including postprandial glucose because fasting measurements may underestimate steroid-related hyperglycemia. Monitoring is recommended within two weeks of starting corticosteroids, after dose increases, and at least every four weeks thereafter until corticosteroids are discontinued or hyperglycemia resolves following dose reduction. Patients with pre-existing type 2 diabetes, newly detected hyperglycemia, or elevated HbA1c should receive a glucose meter and education regarding self-monitoring and warning symptoms, with at least daily testing when glucose remains >10 mmol/L. Surveillance should continue throughout ICI treatment and for 12 months after completion, followed by routine long-term diabetes screening. [2]

Because DKA is common at presentation, all patients with suspected CIADM should undergo capillary ketone testing; elevated ketones or an otherwise unexplained serum bicarbonate <16 mmol/L warrant hospital assessment for possible DKA. The broader assessment algorithm recommends ketone measurement when glucose exceeds 15 mmol/L, or exceeds 10 mmol/L in patients taking an SGLT2 inhibitor. Glucose >15 mmol/L together with ketones >2 mmol/L warrants direct emergency assessment. DKA treatment requires insulin infusion, fluid and electrolyte replacement, and close metabolic monitoring, frequently in an intensive care setting. Patients receiving SGLT2 inhibitors also require education regarding euglycemic DKA and the ability to monitor ketones; if this is impractical, discontinuation of the SGLT2 inhibitor should be considered. [2]

Established CIADM requires lifelong insulin because follow-up findings demonstrate persistent, profound loss of beta-cell function. The proposed initial subcutaneous regimen is once-daily long-acting insulin plus rapid-acting insulin with each of three daily meals. Endocrinology involvement is recommended for initial stabilization, education, and ongoing adjustment, particularly because minimal residual insulin secretion can produce substantial glycemic variability. A general glucose target of 5-10 mmol/L is suggested, with more flexible targets for older or palliative patients and those experiencing frequent unpredictable hypoglycemia. Continuous glucose monitoring and insulin pump therapy should be considered, alongside education about hypoglycemia, sick-day insulin management, ketone monitoring, and DKA. Patients with malabsorptive symptoms should also be assessed for concurrent pancreatic exocrine insufficiency, with pancreatic enzyme replacement considered when fecal elastase is low. Regarding continuation of pembrolizumab or another ICI, the oncology guidelines summarized in the paper recommend withholding treatment during DKA or severe metabolic instability until the acute complication has resolved or the patient is stable; moderate hyperglycemia may also warrant temporary interruption. [2]

A 2026 systematic review and meta-analysis synthesized data from 31 randomized controlled trials (N= 15,417 participants) to evaluate islet function impairment (IFI) outcomes associated with immune checkpoint inhibitors (ICPis) in cancer patients. The majority of trials involved patients with non-small cell lung cancer (NSCLC; n= 8 studies), followed by gastric and/or gastroesophageal cancer (n= 4 studies), melanoma and ovarian cancer (n= 3 each). Treatment regimens compared with either chemoradiotherapy or placebo included pembrolizumab (15), durvalumab (4), nivolumab (3), atezolizumab and avelumab (2 each), and tislelizumab, sugemalimab, cemiplimab, serplulimab, and toripalimab (1 each). The primary outcome was the incidence of IFI which included hyperglycemia, diabetes mellitus (DM), diabetic ketoacidosis( DKA), and type 1 diabetes mellitus (T1DM), with subgroup analyses by ICPi class, individual agent, cancer type, and treatment modality. Overall, ICPis significantly increased the risk of IFI of any grade compared with non-ICPi regimens (risk ratio [RR] 1.30; 95% CI, 1.10–1.53; p= 0.002). ICPi use was also associated with an increased risk of T1DM (RR 3.38; 95% CI, 1.66–6.88; p= 0.0008). Subgroup analyses found significantly increased IFI risk with PD-1 inhibitors (RR 1.53; 95% CI, 1.21–1.93; p= 0.0004), particularly pembrolizumab ((RR 2.38; 95% CI, 1.43–3.97; p= 0.0009) and with NSCLC patients (RR 1.32; 95% CI, 1.01–1.72; p= 0.04). ICPi monotherapy was associated with a significantly higher risk of any-grade and severe IFI (RR 1.43 and 3.39, respectively) than ICPi plus chemotherapy (RR 1.23 and 1.53, respectively). Risk of bias assessments and sensitivity analyses supported the reliability of the findings. The authors emphasized the importance of multidisciplinary monitoring and proactive blood glucose control to facilitate early identification and management of ICPi-associated endocrine complications. [3]

A 2026 network meta-analysis evaluated the comparative risk of endocrine adverse events associated with immune checkpoint inhibitor (ICI)-based regimens versus conventional therapies in patients with colorectal cancer (CRC). The analysis included 6 randomized controlled trials (N= 1,648 patients) and assessed several ICI-based strategies, including pembrolizumab and avelumab monotherapy, ICI combinations with tyrosine kinase inhibitors (TKIs), and ICI combinations with chemotherapy and anti-angiogenic antibodies. Endocrine adverse events evaluated included hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, and diabetes mellitus, with outcomes stratified by severity (all-grade and grade 3–4). [4]

All ICI-containing regimens were associated with an increased risk of endocrine adverse events compared with conventional therapy, with differences across treatment strategies. Pembrolizumab monotherapy and ICI plus TKI regimens were associated with increased hypothyroidism risk (RR 4.44 and 5.62, respectively). Hyperthyroidism risk was significantly elevated with ICI plus TKI and ICI plus chemotherapy and anti-angiogenic antibody combinations. Although thyroiditis, diabetes mellitus, and adrenal insufficiency showed trends toward increased risk, wide confidence intervals limited definitive conclusions. Grade 1–2 events accounted for most of the endocrine toxicity burden, whereas grade 3–4 events were uncommon and estimates were limited by low statistical power. SUCRA rankings identified conventional therapy as having the lowest endocrine toxicity risk, followed by ICI plus chemotherapy and anti-angiogenic antibodies, ICI plus TKI, pembrolizumab, and avelumab regimens. Risk-of-bias assessments indicated moderate methodological quality, with no high-risk domains identified. Overall, ICI-based regimens were associated with increased endocrine toxicity in patients with CRC, predominantly low-grade thyroid dysfunction. These findings support routine endocrine monitoring, particularly thyroid function assessment, during ICI therapy, with attention to differences in toxicity risk across treatment regimens. [4]

Additional meta-analyses have demonstrated increased risks of endocrine-related adverse events associated with ICI-containing regimens, with toxicity profiles varying by drug class and treatment combination. One meta-analysis found that CTLA-4 blockade, particularly ipilimumab, was associated with a higher incidence of hypophysitis (5.6%) compared with nivolumab (0.5%) and pembrolizumab (1.1%), increasing to 10.5% with combined CTLA-4 and PD-1 inhibition. Conversely, thyroid dysfunction was more frequently associated with PD-1/PD-L1 inhibitors. Hypothyroidism incidence ranged from 3.8% with ipilimumab to 8.5% with pembrolizumab, increasing to 15.1% with certain combination regimens. Hypothyroidism risk was significantly elevated across ICIs compared with placebo or chemotherapy (e.g., nivolumab RR 11.19; 95% CI, 4.31–29.08; p <0.001). Diabetes mellitus was less common and primarily associated with PD-1/PD-L1 inhibitors, with reported incidences of 2.0% with nivolumab, 2.0% with pembrolizumab plus ipilimumab, and 0.4% with pembrolizumab monotherapy. [5]

A separate meta-analysis evaluating enfortumab vedotin (EV), alone or combined with pembrolizumab, in patients with advanced urothelial carcinoma found that hyperglycemia occurred in 10.3% of patients (95% CI, 8.6–12.2%), including high-grade events in 5.7% (95% CI, 4.5–7.1%). Compared with control regimens, EV was associated with significantly increased risks of all-grade (RR 16.97; 95% CI, 6.22–48.25) and high-grade hyperglycemia (RR 34.78; 95% CI, 4.77–253.43; both p <0.001). However, hyperglycemia incidence did not significantly differ between EV monotherapy and EV plus pembrolizumab (9.0% vs. 11.5%; p= 0.16), suggesting that adding pembrolizumab did not further increase the hyperglycemia risk associated with EV. The authors noted that inconsistent reporting of corticosteroid use limited assessment of its potential contribution to hyperglycemia risk and highlighted the need for prospective studies to better characterize the risk of hyperglycemia associated with ICI-containing regimens. [6]

Background References: [1] Chitnis SD, Mortazavi A. Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Hosp Med. 2023;18(11):1013-1016. doi:10.1002/jhm.13097
[2] Wu L, Tsang V, Clifton-Bligh R, et al. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer. 2025;13(6):e011271. Published 2025 Jun 8. doi:10.1136/jitc-2024-011271
[3] Hu Q, Fan Y, He P. Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2026;17:1669492. Published 2026 Mar 19. doi:10.3389/fimmu.2026.1669492
[4] Chen B, Liu J, Gan K, et al. A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer. Front Immunol. 2026;17:1798732. Published 2026 Jul 10. doi:10.3389/fimmu.2026.1798732
[5] de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145-156. doi:10.1055/a-0843-3366
[6] Cheng R, Boparai M, Zhu X, Wu S. Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis. Cancer Invest. 2025;43(5):293-304. doi:10.1080/07357907.2025.2502992
Literature Review

A search of the published medical literature revealed 4 studies investigating the researchable question:

Please provide an overview of pembrolizumab-induced diabetes type 1.

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→



Please see Tables 1-4 for your response.


Immune Checkpoint Inhibitors: An Emerging Cause of Insulin-Dependent Diabetes
Design

Retrospective chart review

N= 21 cases

Objective To characterize the frequency, natural history, and potential predictors of immune checkpoint inhibitor (ICI)-induced diabetes
Study Groups

New-onset insulin-dependent diabetes (n= 12)

Worsening of T2D (n= 9)

Inclusion Criteria Patients with cancer treated with ipilimumab, pembrolizumab, or nivolumab at the Mayo Clinic cancer center between January 2012 and December 2017 who, after ICI initiation, either received a new diagnosis of insulin-dependent diabetes or a hyperglycemic crisis or experienced worsening of prediabetes or type 2 diabetes with no other cause (an HbA1c rise of ≥10% within 6 months, a clinical need for a second antihyperglycemic agent or insulin, diabetic ketoacidosis (DKA), or new ketonuria or ketonemia).
Exclusion Criteria Patients with pre-existing type 1 diabetes and those with type 2 diabetes on an insulin pump prior to ICI initiation
Methods Investigators reviewed the charts of every patient in the institutional cancer center database who received a CTLA-4 inhibitor (ipilimumab) or a PD-1 inhibitor (pembrolizumab or nivolumab) over 6 years, with at least 6 months of follow-up after starting an ICI (to capture persistent worsening). Data were collected at three points: at ICI start, at diabetes diagnosis, and at the latest follow-up, and included number of ICI cycles and time to onset, weight change, random and fasting plasma glucose, HbA1c, C-peptide, pancreatic enzymes, pancreatic FDG-PET uptake, type 1 diabetes autoantibodies (GAD65, IA-2, ZnT8, insulin autoantibodies), other immune-related adverse events (IRAEs), glucocorticoid use, and diabetes therapy.
Duration January 2012 to December 2017
Outcome Measures

Frequency of ICI-induced diabetes, time to onset, clinical and laboratory presentation, other IRAEs, diabetes therapy

Baseline Characteristics   New-onset (n= 12) Worsening of T2D (n= 9)
Age, median (IQR), years 67.9 (60.2–71.2) 57.4 (51–62.9)
Male 6 (50%) 6 (66.7%)

Race

White

Black

 

12 (100%)

0 (0%) 

 

8 (88.9%)

1 (11.1%)

Body mass index, kg/m2 32.2 (24.9–37.7) 27.5 (24.9–35.6)
Personal history of autoimmunity 2 (16.7%) 1 (11.1%)
Family history of autoimmunity (n=15) 4/11 (33.3%) 1/4 (11.1%)

Malignancy

Lung cancer

Melanoma

Breast cancer

Renal cell cancer

Multiple myeloma 

Lymphoma

Merkel cell cancer

Esophageal cancer

Pancreatic cancer

 

2 (16.7%)

7 (58.3%)

1 (8.3%)

1 (8.3%)

1 (8.3%)

-

1 (8.3%)

-

-

 

3 (33.3%)

2 (22.2%)

1 (11.1%)

-

-

1 (11.1%)

-

1 (11.1%)

1 (11.1%)

Random plasma glucose, median (IQR), mg/dL 115 (84–140) 158 (107–254)
Fasting plasma glucose, median (IQR), mg/dL 102 (93–108) 132 (114–153)
HbA1c, median (IQR), % - 8 (6.8–8.6)

ICI therapy

Pembrolizumab

Nivolumab

Ipilimumab

 

11 (91.7%)

1 (8.3%)

1 (8.3%)

 

6 (66.7%)

3 (33.3%)

1 (11.1%)

Glucocorticoid use 4 (33.3%)  3 (33.3%)

From a total of 1,444 ICI-treated patients with cancer, 21 patients (1.4%) met criteria for ICI-induced diabetes, of which 12 (0.8%) had new-onset insulin-dependent diabetes, and 9 (0.6%) had unexplained worsening of pre-existing type 2 diabetes.

Out of 1,444 ICI-treated patients, treatment by agent was distributed as follows: Ipilimumab (n= 281), Pembrolizumab (n= 774), Nivolumab (n= 389). Baseline data for the full screened cohort (N= 1,444) were not reported.

Results   New-onset (n= 12) Worsening of T2D (n= 9)
ICI-induced diabetes 12 (100%) 9 (100%)
Time to onset, median (IQR), months 4.9 (2.2–8.1) 3.9 (1.8–10.3)

Clinical and laboratory presentation

Diabetic ketoacidosis

Low/undetectable C-peptide

Pancreatic enzymes: Mildly elevated

Pancreatic enzymes: Moderately-severely elevated (>2 times ULN)

 

8 (66.7%)*

5/6 (83.3%)

1/7 (14.3%

3/7 (42.8%) 

 

0 (0%)

0/1 (0%)

3/7 (42.8%)

1/7 (14.3%)

Other IRAEs

Thyroiditis

Hypophysitis

Dermatitis

Ocular

Hepatitis

Arthritis

6 (50%)

5 (41.7%)

2 (16.7%) 

1 (8.3%)

-

-

1 (8.3%)

7 (77.8%)

4 (44.4%)

1 (11.1%)

1 (11.1%)

1 (11.1%)

1 (11.1%)

-

Diabetes therapy

MDI ± oral agent

Basal insulin ± oral agent

Insulin pump

 

11 (91.7%)

0 (0%) 

1 (8.3%) 

 

7 (77.8%)

2 (22.2%)

0 (0%)

ICI-induced diabetes occurred most frequently with pembrolizumab (2.2%) compared with nivolumab (1%) and ipilimumab (0%).

Autoantibodies were elevated in 5/7 (71%) at the time of new-onset diabetes.

Adverse Events Deaths all from cancer (New-onset vs Worsening of T2D): 1 (8.3%) vs 3 (33.3%)
Study Author Conclusions PD-1 inhibitors can lead to insulin deficiency presenting as new-onset diabetes or worsening of pre-existing type 2 diabetes, with a frequency of 1.8%. The underlying mechanism appears similar to spontaneous type 1 diabetes but there is a faster progression to severe insulin deficiency. Better characterization of ICI-induced diabetes will improve patient care and enhance our understanding of immune-mediated diabetes.
Critique The study provides valuable insights into the frequency and characteristics of ICI-induced diabetes, highlighting the need for monitoring and risk prediction. However, the retrospective nature and limited laboratory characterization for some cases may affect the comprehensiveness of the findings. The study's strength lies in its large cohort and detailed follow-up, but the lack of pre-therapy antibody testing limits the ability to predict diabetes development.

 

Table 1 References:
[7] Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591. Published 2019 Feb 13. doi:10.1136/bmjdrc-2018-000591

 

Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center
Design

Retrospective single-center study

N= 76

Objective To characterize clinical outcomes of patients with immune checkpoint inhibitor diabetes mellitus (ICI-DM) and evaluate the survival impact of this complication on melanoma patients
Study Groups All patients (N= 76)
Inclusion Criteria Patients with new-onset insulin-dependent diabetes with low or undetectable C-peptide level after treatment with ICIs, or those with hyperosmolar hyperglycemic syndrome with low or undetectable C-peptide
Exclusion Criteria Patients with pre-existing Type 1 diabetes mellitus or poorly controlled Type 2 diabetes (HbA1c >8%) receiving insulin therapy
Methods Insulin was administered through multiple daily injections or insulin pump therapy, with median total daily requirements increasing from 0.52 units/kg/day approximately 2.3 weeks after diagnosis to 0.63 units/kg/day at 40 weeks.
Duration April 2014 to December 2020
Outcome Measures

Primary: Characterization of clinical outcomes with long-term follow-up

Secondary: Impact of ICI-DM on survival in melanoma patients

Baseline Characteristics   All patients (n= 76)
Age at presentation, (range) years 60 (32–83)
Male 43 (56.6%)
White 63 (82.9%)
Melanoma 23 (30.3%)
Anti-PD-1 54 (71.1%)
No prior diabetes 64 (84.2%)
BMI, median (IQR) kg/m2 28.3 (23.8–32.3)
Results   HR (95% CI) for ICI-DM on outcomes p-value
Overall survival 1.03 (0.36–2.94) 0.95
Progression-free survival 1.40 (0.76–2.58) 0.29
Time to next treatment 0.97 (0.48–1.94) 0.92
Adverse Events 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis
Study Author Conclusions Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control
Critique The study provides valuable insights into the clinical outcomes of ICI-DM, highlighting the need for early detection and management. However, the retrospective design and single-center nature may limit the generalizability of the findings. Additionally, the study was limited to melanoma patients for survival analysis, which may not reflect outcomes in other cancer types
Table 2 References:
[8] Jeun R, Iyer PC, Best C, et al. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy. 2023;15(6):417-428. doi:10.2217/imt-2021-0316
Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents
Design

Retrospective cohort study

N= 13,966

Objective To review and assess hyperglycemic events across thousands of patients to characterize immune checkpoint inhibitor (ICI)–induced diabetes (ICI-D) using a large-scale trial conglomerate
Study Groups All patients (N= 13,966)
Inclusion Criteria Patients enrolled in an NCI CTEP trial that used a CTEP IND (Investigational New Drug application) and included a PD-1/PD-L1 inhibitor (nivolumab, pembrolizumab, durvalumab, or atezolizumab), alone or with other agents, from June 2015 to December 2022; Case analysis included only patients with ≥1 AE report of grade 3–4 hyperglycemia, acidosis (including DKA), glucose intolerance, or diabetes.
Exclusion Criteria Not specified
Methods

Adverse event reports related to diabetes, hyperglycemia, and acidosis were retrieved from the NCI CTEP database.

Treatment regimens were grouped by ICI class: PD-1/PD-L1 inhibitor alone, or combined with a CTLA-4 inhibitor. Each class was further split by whether it was given with chemotherapy and/or other agents (targeted agents, other immunotherapies, epigenetic modifiers, or antibody-drug conjugates).

Logistic regression was used to calculate the odds of developing ICI-D. Cumulative incidence rates of ICI-D were calculated using trial-level data. Clinical characteristics differentiating ICI-D from other causes of hyperglycemia were enumerated.

Duration June 2015 to December 2022
Outcome Measures

Primary: Cumulative incidence rates of ICI-D

Secondary: Odds of developing ICI-D, clinical characteristics differentiating ICI-D from other causes of hyperglycemia, time to diabetes onset, disease severity and health care burden (hospitalization, ICU admission)

Baseline Characteristics   All patients (N= 72)*
Age, mean (range), years 56.9 (12-79)
Female 28 (38.9%)

Race

White

Black

Unknown

 

66 (91.7%)

4 (5.6%)

2 (2.8%)

Ethnicity

Non-Hispanic

Hispanic

Unknown

 

61 (84.7%)

9 (12.6%)

2 (2.8%)

Cancer**

Melanoma

Renal cell carcinoma

Anal cancer

Hodgkin lymphoma

Ovarian/fallopian

Urothelial tract/bladder

 

20 (27.78%)

17 (23.61%)

4 (5.56%)

4 (5.56%)

4 (5.56%)

4 (5.56%)

Treatment: ICI Exposure

Combination PD-1/CTLA-4 inhibitor

PD-1 inhibitor monotherapy

PD-L1 inhibitor monotherapy

 

34 (47.22%)

32 (44.44%)

6 (8.33%)

Hypothyroidism

10 (13.89%)

Family history of T1D

Yes

Unknown

 

6 (8.33%)

37 (51.39%)

*Baseline characteristics were reported only for the 72 ICI-D cases, not for the full exposed cohort (N= 13,966).

**Most common cancer types (≥5% of patients).

Results   Incidence Total No. exposed p-value
Overall incidence 0.52 13,966 -

ICI type

Combination (PD-1/PD-L1 + CTLA-4 inhibitor therapy)

PD-1/PD-L1 inhibitor therapy

 

0.94

0.37

 

3,520

10,446

<0.001

 

 

Combination with chemotherapy

ICI with chemotherapy

ICI without chemotherapy

 

0.26

0.65

 

4,666

9,300

0.002

 

 

The time from ICI initiation to diagnosis of diabetes did not vary substantially across etiologies of diabetes. The time from ICI initiation to ICI-D diagnosis was faster in patients with IAs at diabetes diagnosis but was no different based on presentation in diabetic ketoacidosis, thyroid autoimmunity, elevated lipase levels, and ICI therapy class.

Higher glucose levels were more likely to be due to ICI-D. An optimal cut point of 513 mg/dL provides a sensitivity of 76% and specificity of 73% to distinguish between ICI-D and other forms of diabetes. 

Adverse Events

Despite low incidence rates, the health care burden of ICI-D was high, with 90% requiring hospitalization at diagnosis and 43% requiring intensive care.

Among the 157 patients with grade 3–4 hyperglycemia or acidosis reports, ICI-D accounted for 45.9% and steroid-induced diabetes for 38%. Thyroid IRAEs occurred in 23.6% of ICI-D cases.

Study Author Conclusions Results of this study suggest that ICI-D is a rare but morbid condition that varies based on the combination of ICIs with other agents. Rates of ICI-D vary substantially across treatment types and vary across cancer types, likely related to indications for use of various immunotherapy combinations.
Critique The study provides a comprehensive analysis of ICI-D across multiple institutions and cancer types, offering valuable insights into the incidence and characteristics of ICI-D. However, the retrospective nature and potential underreporting within the NCI CTEP AE database, particularly for late-onset cases or less-severe diabetes presentations, may limit the findings. Additionally, the lack of certain patient-level covariates could influence ICI-D incidence rates through confounding.

 

Table 3 References:
[9] Quandt ZE, Finnigan S, Hill V, et al. Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents. JAMA Oncol. 2026;12(2):194-199. doi:10.1001/jamaoncol.2025.5594
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Design

Retrospective cohort study

N= 14,328

Objective To define incidence, risk factors, and clinical spectrum of an irreversible and life-threatening irAE: ICI-induced diabetes
Study Groups

ICI-treated patients (n= 14,328)

ICI-induced diabetes (n= 64)

Inclusion Criteria Adult patients treated with ICIs in the Mass General Brigham system from July 2010 to January 2022
Exclusion Criteria Patients with type 1 diabetes before ICI treatment, taking high-dose steroids at the time of diabetes diagnosis, not on insulin
Methods Data were collected from initial ICI exposure until death or November 1, 2022. Demographic characteristics, diagnosis codes, medications, and laboratory studies were extracted from a centralized MGB database. ICI-induced diabetes was defined as a new, permanent loss of β-cell function following treatment with ICI. T1D polygenic score (T1D GRS2) was calculated for patients with available genotyping data.
Duration July 2010 to January 2022
Outcome Measures

Primary: Prevalence and incidence of ICI-induced diabetes

Secondary: Risk factors and clinical spectrum of ICI-induced diabetes

Baseline Characteristics   Without ICI-induced diabetes (n = 14,264) ICI-induced diabetes (n = 64) p-value
Age, median (IQR), years 66 (57-73) 62.5 (56-69) 0.44
Female 6,539 (46%) 32 (50%) 0.51

Comorbidities

Type 2 diabetes

Hyperlipidemia

Hypertension

Coronary artery disease

Cirrhosis

Congestive heart failure

Chronic kidney disease

 

762 (5.3%)

1,851 (13.0%)

2,758 (19.3%)

1,498 (10.5%) 

117 (0.8%)

365 (2.6%)

654 (4.5%)

 

16 (25%)

10 (15.6%)

12 (18.8%)

11 (17.2%)

0 (0%)

1 (1.6%)

6 (9.4%)

 

<0.001

0.53

0.91

0.08

0.47

0.61

0.07

Tumor category*

Breast

Genitourinary

Melanoma

Thoracic

 

760 (5.3%)

1,730 (12.1%)

2,158 (15.1%)

4,312 (30.2%)

 

5 (7.8%)

9 (14.1%)

23 (36.0%)

15 (23.4%)

 

0.38

0.64

<0.001

0.24

ICI class

Anti-PD-1

Anti-PD-L1

Anti–CTLA-4

Combination (anti–CTLA-4 + anti–PD-1/PD-L1)

Other/unknown

 

10,191 (71.5%)

1,968 (13.8%)

574 (4.0%)

1,515 (10.6%)

16 (0.1%)

 

43 (67.2%)

4 (6.3%)

2 (3.1%)

15 (23.4%)

0 (0%)

 

0.46

0.05

0.70

0.003

0.71

*Most common in both groups (≥5%)
Results Clinical Spectrum (n= 56)* Ab+β− (n = 23) Ab−β− (n = 26) p-value
Preexisting dysglycemia 9 (39%) 7 (27%) 0.54
HbA1c at diagnosis, median (IQR),% 8.4 (7.8-9.4) 7.8 (7.2-9.3)  0.63
DKA at diagnosis 14 (61%) 9 (35%) 0.09
Elevated lipase after ICI 10 (43%) 1 (4%) 0.001
Time from ICI to diagnosis, median (IQR), days 59 (42-115.5) 166.5 (113.3-266) <0.001

Prevalence of ICI-D was 64/14,328 (0.45%).

Incidence of ICI-D was 124.8 per 100,000 person-years (about 51,272 person-years of follow-up).

Preexisting type 2 diabetes (odds ratio [OR], 5.91; 95% CI, 3.34-10.45), melanoma (OR, 4.02; 95% CI, 3.58–4.52), and treatment with combination ICI (OR, 2.57; 95% CI, 1.44-4.59) were significant clinical risk factors for ICI-induced diabetes. There was no significant difference between PD-1/PD-L1 and CTLA-4 monotherapy.

A higher T1D polygenic score (T1D GRS2) was associated with ICI-D. Patients in the top decile had about 4.4-fold higher risk (HR 4.4; 95% CI, 1.8–10.5).

*C-peptide level data was available for 56 patients (Ab+β−= preserved β-cell function; Ab−β−= low or undetectable β-cell function).

Adverse Events

Diabetes-related hospitalization within 1 year of diagnosis occurred in 19 (30%) ICI-D patients.

Permanent ICI discontinuation occurred in 12 (19%) ICI-D patients.

Study Author Conclusions Using validated multimodal approaches, we defined ICI-induced diabetes, revealing its prevalence, risk factors, and underlying disease heterogeneity. Our findings may empower physicians to identify individuals at high risk of ICI-induced diabetes and guide ICI initiation and therapeutic planning accordingly. Widespread adoption of this approach may optimize irAE diagnosis and management across diverse clinical scenarios.
Critique The study's strengths include a large sample size and comprehensive analysis of risk factors and phenotypic subtypes. However, its retrospective nature may limit the ability to establish causality, and potential selection bias in genetic analyses due to the PROFILE study cohort may affect generalizability.

 

Table 4 References:
[10] Ruiz-Esteves KN, Shank KR, Deutsch AJ, et al. Identification of Immune Checkpoint Inhibitor-Induced Diabetes. JAMA Oncol. 2024;10(10):1409-1416. doi:10.1001/jamaoncol.2024.3104